XOMA News and Press, XOMA Corporation From 11/05/20

Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing res...

XOMA (XOMA) has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies (BIOAF), associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders ((LSD)) under Bioasis’ strategic all...

EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes being investig...

XOMA's (XOMA) NIS793, an anti-TGFβ monoclonal antibody has advanced to the Phase 2 stage. The event has triggered a $25M milestone payment from Novartis.The Phase 2 trial is designed to assess the efficacy and safety of NIS793 in first-line metastatic pancreatic ductal adenocarcinoma.&...

EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25 million milestone payment from Novartis.  The Phase ...

Xoma (XOMA) has earned $1.9M in payments from two partners, $1.4M from Rezolute, in connection with its recent private placement to develop clinical candidates, RZ358 and RZ402 and $0.5M milestone payment from a partner regarding advancement of undisclosed asset into Phase 2 clinical developm...

Rezolute ’s recent private placement triggers $1.4 million payment to XOMA In an unrelated development, a partner initiated Phase 2 development of an undisclosed asset , which triggers $0.5 million milestone payment to XOMA EMER...

The following slide deck was published by XOMA Corporation in conjunction with this Read more ...

EMERYVILLE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference.  The presentation will take pl...

XOMA (NASDAQ: XOMA ) : Q2 GAAP EPS of -$0.33 beats by $0.05 . More news on: XOMA Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...